Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of papaverine (PPV) in combination with radiation therapy (RT) for locally advanced rectal cancer (LARC).

II. Describe the safety and tolerability of PPV in combination with standard of care (SOC) RT for LARC.

SECONDARY OBJECTIVES:

I. Determine the clinical complete response rate (cCR), and local-regional control rate of PPV in combination with RT for LARC.

II. Determine the total mesorectal excision (ToME)-free survival, local-regional recurrence free survival (LRRFS), disease-free survival (DFS), distant-metastasis-free survival (DMFS) and overall survival (OS) of PPV in combination with RT for LARC.

EXPLORATORY OBJECTIVES:

I. Determine whether PPV in combination with RT for LARC directly results in reduced tumor hypoxia.

II. Explore whether RT with and without mitochondrial oxygen consumption (MOC) inhibition alters the tumor immune microenvironment (TIME) in patients receiving SOC RT for LARC.

III. Explore whether molecular profiling (changes in hypoxia-induced gene expression, immune cell tumor infiltrates and peripheral immune profiling) can predict which patients may respond best to PPV in combination with SOC RT for LARC.

IV. Explore whether stool microbial signatures are associated with response to or progression after PPV in combination with SOC RT for LARC.

OUTLINE: This is a dose escalation study of PPV in combination with RT followed by a dose-expansion study. Patients are randomized to 1 of 2 cohorts.

COHORT 1: Patients undergo RT once daily (QD) on days 1-5 (Monday-Friday) of week 1. Starting at week 5, patients receive SOC consolidation chemotherapy (CC) with either modified leucovorin, fluorouracil, oxaliplatin-6 (mFOLFOX6) or capecitabine-oxaliplatin (CAPOX) for 3-4 months in the absence of disease progression or unacceptable toxicity. As early as four weeks following completion of CC, patients with persistent disease (non-cCR) or disease recurrence in the rectum during disease evaluation may undergo ToME. Additionally, patients undergo one functional magnetic resonance imaging (fMRI) on study as well as computed tomography (CT), magnetic resonance imaging (MRI), endoscopy, and blood and tissue sample collection throughout the trial.

COHORT 2: Patients receive PPV intravenously (IV) over 15-30 minutes on day -3 of week 0 and days 1-5 of week 1. Patients also undergo RT QD on days 1-5 (Monday-Friday) of week 1, 1-2 hours after PPV. Starting at week 5, patients receive SOC CC with either mFOLFOX6 or CAPOX for 3-4 months in the absence of disease progression or unacceptable toxicity. As early as four weeks following completion of CC, patients with persistent disease (non-cCR) or disease recurrence in the rectum during disease evaluation may undergo ToME. Additionally, patients undergo two fMRI on study as well as CT, MRI, endoscopy, and blood and tissue sample collection throughout the trial.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for an additional 3 years.

Inclusion criteria

• Documented informed consent of the participant and/or legally authorized representative
• Willingness to participate in all correlative studies: fMRI, and tissue collection of tumor and normal rectum (ribonucleic acid [RNA]/deoxyribonucleic acid [DNA]/protein), blood (plasma/peripheral blood mononuclear cell [PBMC]) draws and stool collection
• Age: ≥ 18 years
• Eastern Cooperative Oncology Group (ECOG) ≤ 2
• Histologically confirmed rectal adenocarcinoma
• Patient wants to pursue an organ preservation/non-operative management (NOM) approach after completion of total neoadjuvant therapy (TNT)
• Locally advanced rectal cancer (T3-4 or node+, M0)
• Tumor is microsatellite stable (MSS) (defined as not microsatellite instability-high [MSI-H] or mismatch repair deficient [dMMR])
• Absolute neutrophil count (ANC) ≥ 1,500/mm^3 (within 30 days of start). NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
• Platelets ≥ 100,000/mm^3 (within 30 days of start). NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
• Hemoglobin ≥ 9g/dL (within 30 days of start). NOTE: Red blood cell transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement
• Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (within 30 days of start)
• Aspartate aminotransferase (AST) =< 2.5 x ULN (within 30 days of start)
• Alanine aminotransferase (ALT) =< 2.5 x ULN (within 30 days of start)
• Creatinine clearance of ≥ 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula (within 30 days of start)
• For patients with known infections only: seropositive for HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV), nucleic acid quantitation must be performed. Viral load must be undetectable. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial (within 28 days of start)
• Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (within 30 days of start)
• Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 4 months after the last dose of protocol therapy

• Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion criteria

• Chemotherapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter) prior to day 1 of protocol therapy
• Prior pelvic irradiation resulting in overlapping fields
• Use of levodopa in the last 30 days
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
• Unable to undergo MRI and endoscopic procedures
• History of complete atrioventricular block, hepatic dysfunction (e.g. cirrhosis), or priapism
• Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
• Females only: Pregnant or breastfeeding
• Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)